Prospects for Monoclonal Antibody Therapy in Pediatric Asthma.

doi:10.1007/s11882-018-0799-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Prospects for Monoclonal Antibody Therapy in Pediatric Asthma.

Current allergy and asthma reports - 10 Jul 2018

Generoso August, Muglia-Chopra Christine, Oppenheimer John

Abstract excerpt

PURPOSE OF REVIEW: The profile of biologic therapies for asthma is growing rapidly. We discuss how to match the proper pediatric patient with the most effective therapy. RECENT FINDINGS: Currently available biologic therapies are most effective in patients with T2 high asthma. Newer drugs are currently being studied which target TSLP and interleukin 33. These newer drugs may provide options for asthmatics who do...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Asthmatic Agents
Share to Antibodies, Monoclonal
Share to Asthma
Share to Child
Share to Cytokines
Share to Immunotherapy
Share to Interleukin-33
Share to Thymic Stromal Lymphopoietin

Source

Open in PubMed

Identifiers

PMID: 29992472
DOI: 10.1007/s11882-018-0799-1

Genes

TSLP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics